Psyence Biomedical Ltd. Common Shares (PBM)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Viewed through a Graham lens, Psyence is not an operating business so much as a clinical-stage speculation. It has 12 employees, no revenue growth figure, and its lead candidate NPX-5 is only in Phase IIb for adjustment disorder in palliative cancer. FairStock’s price-based calculations at the 2026-10-13 close of $4.55 show a negative P/E of -0.36 and a P/B of 0.62. A P/B below one might attract a deep-value investor, but in biotechnology book value is often cash being consumed, not productive assets. The returns confirm the burn: ROE is -58.62% and ROCE is -31.33%. The Piotroski F-Score of 1/9 is very weak, indicating poor fundamental momentum, even though the Altman Z-Score of 6.96 suggests low near-term bankruptcy risk by that measure. Market capitalization is only $20.0M, beta is 1.69, and the 52-week range of $1.92 to $140.00 shows how speculative the shares have been. FairStock Score is 32/100, and there is no Lynch category because there are zero years of filed annual results; there is no durable record to underwrite. A moat? I see none in the supplied figures. Any future moat would have to come from intellectual property, trial data, or partnerships, none of which can be verified here. Growth depends entirely on clinical success. I prefer predictable earnings, honest book value, and a margin of safety. Here the margin of safety is theoretical unless the balance sheet is cash-rich and burn is controlled. Until NPX-5 data or partnerships prove otherwise, this is not a business I would call investment-grade.

In plain English: Psyence Biomedical is a very small biotech with 12 employees, working on a psilocybin-based medicine for adjustment disorder in cancer palliative care. The business is not yet profitable, has no revenue growth figure in the data, and looks financially weak. At the 2026-10-13 close of $4.55, the price looks low compared with accounting net assets, but the heavy losses and weak financial scores make that apparent cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer